Alan Pestronk is a Neurology physician affiliated with Washington University in St. Louis. OpenAlex indexes 388 publications with 29,403 citations (h-index 95); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Neurology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Neurology Adult, Ste 6c
Saint Louis, MO 631101032
Telephone
314-362-1408Registry record last updated 17 Apr 2025.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20252 payments
- PFIZER INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
58.5%Gabapentinoids18.6%Gabapentin55%Pregabalin45%Part D<11 patientsOpioid Agonist16.9%Tramadol Hcl39%Fentanyl37%Oxycodone Hcl24%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
21.9%Corticosteroid21.9%Prednisone100%Part D≥22 patientsMusculoskeletal
19.6%Survival of Motor Neuron 2 Splicing Modifier19.6%Evrysdi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 1989–2007 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
New England Journal of Medicine
2020 - Congenital Titinopathy: Comprehensive characterization and pathogenic insights
Annals of Neurology
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”